Dimensional Fund Advisors LP Has $62.58 Million Holdings in AngioDynamics, Inc. (ANGO)

Share on StockTwits

Dimensional Fund Advisors LP decreased its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 0.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,108,678 shares of the medical instruments supplier’s stock after selling 11,418 shares during the quarter. Dimensional Fund Advisors LP owned 0.08% of AngioDynamics worth $62,578,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ANGO. Legal & General Group Plc lifted its holdings in shares of AngioDynamics by 9.9% in the third quarter. Legal & General Group Plc now owns 79,643 shares of the medical instruments supplier’s stock valued at $1,728,000 after buying an additional 7,184 shares during the period. Vanguard Group Inc. lifted its holdings in shares of AngioDynamics by 2.0% in the third quarter. Vanguard Group Inc. now owns 2,144,291 shares of the medical instruments supplier’s stock valued at $46,617,000 after buying an additional 42,134 shares during the period. First Quadrant L P CA lifted its holdings in shares of AngioDynamics by 143.6% in the fourth quarter. First Quadrant L P CA now owns 12,950 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 7,633 shares during the period. Quantamental Technologies LLC acquired a new stake in shares of AngioDynamics in the fourth quarter valued at $67,000. Finally, Arizona State Retirement System lifted its holdings in shares of AngioDynamics by 6.3% in the fourth quarter. Arizona State Retirement System now owns 57,167 shares of the medical instruments supplier’s stock valued at $1,151,000 after buying an additional 3,385 shares during the period. Hedge funds and other institutional investors own 99.93% of the company’s stock.

Several brokerages have recently weighed in on ANGO. BidaskClub lowered AngioDynamics from a “hold” rating to a “sell” rating in a report on Wednesday, April 24th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a report on Thursday, May 16th. TheStreet lowered AngioDynamics from a “b” rating to a “c+” rating in a report on Thursday, April 18th. Finally, ValuEngine lowered AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, April 19th. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. The company has a consensus rating of “Hold” and an average price target of $23.50.

Shares of AngioDynamics stock opened at $19.27 on Friday. The firm has a market cap of $721.99 million, a PE ratio of 26.04 and a beta of 0.68. The company has a current ratio of 2.68, a quick ratio of 1.70 and a debt-to-equity ratio of 0.23. AngioDynamics, Inc. has a 12-month low of $18.11 and a 12-month high of $25.48.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, April 2nd. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.03). The company had revenue of $86.34 million for the quarter, compared to analyst estimates of $88.30 million. AngioDynamics had a return on equity of 5.41% and a net margin of 1.30%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $0.23 earnings per share. Equities research analysts predict that AngioDynamics, Inc. will post 0.83 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Zolmax and is the sole property of of Zolmax. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://zolmax.com/investing/dimensional-fund-advisors-lp-has-62-58-million-holdings-in-angiodynamics-inc-ango/3094702.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Further Reading: Are all No-Load Funds Equal?

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: Diamondback Energy Inc  VP Sells $536,400.00 in Stock
Insider Selling: Diamondback Energy Inc VP Sells $536,400.00 in Stock
Insider Selling: Gran Colombia Gold Corp  Senior Officer Sells C$836,403.50 in Stock
Insider Selling: Gran Colombia Gold Corp Senior Officer Sells C$836,403.50 in Stock
Low & Bonar  Rating Reiterated by Peel Hunt
Low & Bonar Rating Reiterated by Peel Hunt
BidaskClub Lowers Automatic Data Processing  to Hold
BidaskClub Lowers Automatic Data Processing to Hold
Head-To-Head Analysis: ENDRA Life Sciences  & Its Competitors
Head-To-Head Analysis: ENDRA Life Sciences & Its Competitors
Autodesk  versus Textmunication Holdgings  Critical Comparison
Autodesk versus Textmunication Holdgings Critical Comparison


 
© 2006-2019 Zolmax.